Eli Lilly and Company is a global pharmaceutical leader focused on developing medicines in various areas. Founded in 1876, the company operates in over 100 countries. Its stock performance has been strong in 2025, outperforming the S&P 500. In Q3 2025, Eli Lilly reported revenue of $17.6 billion, exceeding analyst estimates.

The company’s adjusted EPS reached $7.02, beating consensus forecasts. Gross margin improved to 82.9%, with strong operating cash flow. For full-year 2025, Eli Lilly raised revenue guidance to $63-63.5 billion and adjusted EPS to $23-23.70. The company is reducing prices for the weight-loss drug Zepbound on its platform.

Eli Lilly’s move to lower Zepbound prices follows President Trump’s deals to enhance access to weight-loss drugs. The company aims to increase affordability despite the drug’s list price. Analysts rate Eli Lilly as a “Strong Buy” with a mean price target of $1,041.60, cautioning potential investors due to the stock trading slightly above the target price.

Read more at Yahoo Finance: As Eli Lilly Cuts Zepbound Prices, Should You Buy, Sell, or Hold LLY Stock?